Depression

Many people believe World War II ended the Great Depression. Yes and No. Our industry demanded the government guarantee them significant profits if they switched to making weapons. The Federal Government would not guarantee profits. Therefore, those industries kept on producing many consumer goods including new cars throughout 1941 and into 1942. Meanwhile, Hitler’s forces […]

More than half of the Detroit public school students assessed in a mental health survey said they experienced symptoms of anxiety or depression and 23% seriously considered attempting suicide before the pandemic, according to a new report. Of 11,000 Detroit Public Schools Community District students who responded to a mental health assessment by the district in collaboration with a

  Pivotal Phase III trial results show Sage Therapeutics and Biogen’s investigational depression drug, zuranolone, significantly reduced depressive symptoms after two weeks of treatment compared with placebo.  The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD). Investigational zuranolone is an oral neuroactive steroid GABA-A receptor

Meryl Streep’s last experience of method acting left her “so depressed”. The 71-year-old actress immersed herself in the role of Runway editor Miranda Priestly in 2006 movie ‘The Devil Wears Prada’ both on and off camera, but hated being isolated away from the rest of the cast because she could always hear them having a

Do you feel as though we’re in the middle of an epidemic of mental health disease? If the answer is yes, you’re not alone. I think that most clinicians are feeling this. And it certainly seems like the pandemic is not helping the situation. Thus, the question of how best to screen adolescents for depression

Text size Sage is in a partnership with Biogen on zuranalone. Dreamstime Sage Therapeutics said early Tuesday that its drug zuranalone reduced depression symptoms in a Phase 3 trial, but the results seem to have befuddled investors. The stock fell as low as $57 in premarket trading from $72.86 at the market close on Monday,

Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designation Advancing Ketamine and KETABET™ alone or in a microneedle patch for intradermal administration Potential next generation treatment for mental health, neurological and pain disorders TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a

Looking to make a comeback after a big Phase III flop, Sage Therapeutics revealed data they believe could change the entire depression treatment landscape, given the vast array of failures in the field. But some results are spooking investors, sending Sage $SAGE shares down early Tuesday. First, the primary: Sage and Biogen reported Phase III

In 2015, University of Chicago Prof. Peter Nagele became interested in exploring the effects of nitrous oxide, commonly known as “laughing gas”—not for dental procedures, as most people associate it with, but for treating severe depression. A new study by Nagele and colleagues at UChicago and Washington University in St. Louis found that a single inhalation

Study data published in JAMA support the efficacy of a digital intervention for depressive symptoms among patients with hypertension or diabetes. In randomized clinical trials (RCTs) conducted in Brazil and Peru, patients displayed significant improvements in depression symptoms following digital treatment. However, results were not sustained at 6 months. Depression is a known risk factor